To evaluate KLK2 as a potential therapeutic target for T-cell engagers, we developed a bispecific antibody, KLK2 × CD3, which binds to CD3 receptor complexes on T cells and KLK2 on the surface of prostate tumor cells. The gene discussed is KLK2; the disease is prostate neoplasm.